The company could rival Vertex and Lilly in the burgeoning market for non-opioid, ion-channel-blocking pain drugs. Its offering also adds to a recent and significant uptick in large biotech IPOs.
An article from
Pain drugs
The company could rival Vertex and Lilly in the burgeoning market for non-opioid, ion-channel-blocking pain drugs. Its offering also adds to a recent and significant uptick in large biotech IPOs.
Published Aug. 7, 2026
Nasdaq MarketSite headquarters in New York, N., on Aug. 21, 2022.
BlossomHill, Latigo cap four-IPO week with combined $496M haul
Eli Lilly’s Obesity Drugs Drive Massive Revenue Growth
Attovia extends biotech IPO streak with $289M listing for three I&I drugs
Read Between These Lines As Lilly, Hot IPO And More Face Key Test
